|
Carcinoma of urinary bladder, invasive
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> S100A16 contributes to the chemoresistance of NMIBC by promoting the AKT/Bcl-2-mediated anti-apoptosis effect and could be a potential prognostic marker and therapeutic target for NMIBC patients.
|
31118765 |
2019 |
|
Fibrosis, Liver
|
0.050 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The novel findings of this study suggested that SA-A could reduce liver fibrosis and the molecular mechanisms behind it are closely associated with the regulation of PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways.
|
31213776 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<B>Conclusions</B>: These findings suggest that maternal hypoxia may exacerbate hippocampal cell apoptosis in rat offspring after MCAO via alterations in the expression of cytochrome c, caspase-3, Bax, and bcl-2, which ultimately affects ischemic stroke prognosis.
|
29363906 |
2017 |
|
Carcinoma of urinary bladder, invasive
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Bcl-2 status is not an independent predictor of neoadjuvant cisplatin chemotherapy response and is not prognostic in muscle-invasive bladder cancer.
|
30806186 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusions:</b> Our study indicated that FAM111B might be an oncogene and potential therapeutic target in LUAD which could be involved in the regulation of tumor cells by p53 signaling pathway and play an important role in the process of cell cycle and apoptosis by influencing the expression of BAG3 and BCL2.
|
31114230 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Introduction</b>: Myeloid cell leukemia-1 (MCL-1) is an anti-apoptotic member of the B-cell lymphoma-2 (BCL-2) family of proteins that regulates apoptosis.
|
31566022 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> B-cell lymphoma-2 (BCL-2), an antiapoptotic protein often dysregulated in B-cell lymphomas, promotes cell survival and provides protection from stress.
|
29666304 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> Clinically available BH3 mimetic drugs targeting BCLXL and/or BCL2 (navitoclax and venetoclax, respectively) are effective in some hematologic malignancies, but have limited efficacy in solid tumors.
|
30021909 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Purpose:</b> Clinically available BH3 mimetic drugs targeting BCLXL and/or BCL2 (navitoclax and venetoclax, respectively) are effective in some hematologic malignancies, but have limited efficacy in solid tumors.
|
30021909 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del(17p)] or progressive disease following B-cell receptor pathway inhibitors.<b>Patients and Methods:</b> We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three phase I/II studies.<b>Results:</b> Median age was 66 years and 60% had del(17p).
|
29895707 |
2018 |
|
Progressive Neoplastic Disease
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
<b>Purpose:</b> The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del(17p)] or progressive disease following B-cell receptor pathway inhibitors.<b>Patients and Methods:</b> We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three phase I/II studies.<b>Results:</b> Median age was 66 years and 60% had del(17p).
|
29895707 |
2018 |
|
Progressive cGVHD
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del(17p)] or progressive disease following B-cell receptor pathway inhibitors.<b>Patients and Methods:</b> We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three phase I/II studies.<b>Results:</b> Median age was 66 years and 60% had del(17p).
|
29895707 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<i>ANGPTL1</i> promoted apoptosis via inhibition of the STAT3/Bcl-2-mediated antiapoptotic pathway and decreased cell migration and invasion via downregulation of transcription factors SNAIL and SLUG.
|
28904065 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<i>In situ</i> hybridization was performed to determine the positive rate of miR-340 expression while immunohistochemistry was used to determine that of CTNNB1 and B-cell lymphoma 2 (Bcl-2).
|
29769415 |
2018 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<i>In vivo</i>, the MI mice exhibited worse cardiac function by echocardiographic assessment and showed larger myocardial scarring by light microscopy, whereas aliskiren treatment reversed these effects, which were also associated with the changes in caspase-3 and Bcl-2 expression as well as in the number of apoptotic cells.
|
29184499 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>MYC/BCL2</i> DHL, <i>MYC/BCL6</i> DHL and MYC/BCL2 DEL are an aggressive B cell lymphoma and patients have a poor prognosis.
|
31615842 |
2020 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<i>Results:</i> The expression of miR-125a-5p in breast cancer cell lines, MDA-MB-157 cells, MDA-MB-361 cells and MDA-MB-415 cells, was significantly lower than that in normal breast epithelial cells, MCF-10A cells; The proliferation and invasion ability of MDA-MB-157 cells transfected with miR-125a-5p were significantly inhibited, and the apoptosis rate was significantly increased; Since GAB2 knocked down, the proliferation and invasion ability of MDA-MB-157 cells were significantly inhibited, while the apoptosis rate was significantly increased, the Bax protein expression was significantly down-regulated, and the Bcl-2 protein expression was significantly up-regulated; The dual-luciferase reporter assay demonstrated that miR-125a-5p can specifically target GAB2.
|
31698596 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<i>Results:</i> The expression of miR-125a-5p in breast cancer cell lines, MDA-MB-157 cells, MDA-MB-361 cells and MDA-MB-415 cells, was significantly lower than that in normal breast epithelial cells, MCF-10A cells; The proliferation and invasion ability of MDA-MB-157 cells transfected with miR-125a-5p were significantly inhibited, and the apoptosis rate was significantly increased; Since GAB2 knocked down, the proliferation and invasion ability of MDA-MB-157 cells were significantly inhibited, while the apoptosis rate was significantly increased, the Bax protein expression was significantly down-regulated, and the Bcl-2 protein expression was significantly up-regulated; The dual-luciferase reporter assay demonstrated that miR-125a-5p can specifically target GAB2.
|
31698596 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
<i>Results:</i> The expression of miR-125a-5p in breast cancer cell lines, MDA-MB-157 cells, MDA-MB-361 cells and MDA-MB-415 cells, was significantly lower than that in normal breast epithelial cells, MCF-10A cells; The proliferation and invasion ability of MDA-MB-157 cells transfected with miR-125a-5p were significantly inhibited, and the apoptosis rate was significantly increased; Since GAB2 knocked down, the proliferation and invasion ability of MDA-MB-157 cells were significantly inhibited, while the apoptosis rate was significantly increased, the Bax protein expression was significantly down-regulated, and the Bcl-2 protein expression was significantly up-regulated; The dual-luciferase reporter assay demonstrated that miR-125a-5p can specifically target GAB2.
|
31698596 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Solanum nigrum</i> polysaccharide inhibits tumor growth in H22-bearing mice through regulation of caspase-3 and bcl-2.
|
29578179 |
2018 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases.
|
17652637 |
2007 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
LHGDN |
''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases.
|
17652637 |
2007 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
'Double-hit lymphomas' (DHL), defined by concurrent MYC and BCL2 (or, alternatively, BCL6) rearrangements, have a very poor outcome compared to standard-risk, diffuse large B-cell lymphomas (DLBCL).
|
25907897 |
2015 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
'Double-Hit' (DH) B cell non-Hodgkin lymphomas are characterized by the presence of a MYC rearrangement and additional rearrangement(s) most commonly involving BCL2 and/or BCL6.
|
24761809 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
'Double-hit' lymphoma (DHL) and 'double-expression' lymphoma (DEL) involving gene rearrangement and protein expression of MYC and BCL2/BCL6 have recently become the most commonly used terms to describe the poor prognostic types of diffuse large B-cell lymphoma (DLBCL).
|
31615842 |
2020 |